MedTrace Logo

Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression

NCT06140082 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 477

Last updated 2023-11-18

No results posted yet for this study

Summary

This study intends to design a retrospective and prospective, cohort study to explore the association between genetic polymorphism of GSTP1 A313G rs1695 or others and adverse effects of platinum drugs, aiming to explore the risk factors of myelosuppression caused by platinum drugs, and provide data support for optimizing anti-tumor chemotherapy regimen, improve medication safety and improve the compliance of chemotherapy in patients.

Conditions

Interventions

GENETIC

GSTP1 A313G （AA）

Patients with pulmonary malignant tumors receiving platinum-containing chemotherapy regimen were included in the retrospective and prospective bidirectional cohort study to collect the basic information of the subjects, including gender, age, smoking history, primary site, basic liver and kidney function, chemotherapy regimen, etc. The polymorphisms of glutathione S transferase (GSTP1 A313G) were detected by Sanger dideoxy termination sequencing. The wild type (AA) and mutant type (AG/GG) were divided into two groups.

Sponsors & Collaborators

  • LI YAN

    lead OTHER

Principal Investigators

  • Peng Jing, doctor · Jining Medical University

  • Guo Nan, doctor · Shandong Provincial Hospital

  • Guo LuBo, doctor · Jinan Municipal Central Hospital

  • Liu Lun, doctor · Tai 'an City Central Hospital

  • Zhang ZongLin, doctor · Linyi People's Hospital

  • Di HuiFeng, doctor · Jinan Municipal People's Hospital

  • Sun DeQing, doctor · The Second Hospital of Shandong University

  • Zhang XiaoLi, doctor · Shandong Province Third hospital

  • Liu JianFang, doctor · People's Hosital of Rizao

  • si JiGang, doctor · Zibo Central Hospital

  • Chen HaiSheng, doctor · Shandong Provincial Tumor Hospital

  • Bi HengTai, doctor · Weifang Central Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2025-12-01
Completion
2025-12-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06140082 on ClinicalTrials.gov